JETIR.ORG ISSN: 2349-5162 | ESTD Year : 2014 | Monthly Issue
JOURNAL OF EMERGING TECHNOLOGIES AND INNOVATIVE RESEARCH (JETIR)
An International Scholarly Open Access, Peer-reviewed, Refereed Journal

CAR T-Cell Therapy: A New Horizon in Cancer Treatment

[1]Gore Akash Balaji, [2]Guntapalle Jalba Balaji, [3]Bharde Vikrant Parmeshwar,

[4]Gundare Santosh Rajendra

[1,2,3,4]Student

Shivlingeshwar College of Pharmacy, Almala

Abstract

Chimeric antigen receptor (CAR) T-cell therapy is a revolutionary approach to delivering treatment in cancer conditions and, in particular, has become a beacon of hope for patients suffering from hematological malignancies as well as solid tumors. The biological uniqueness of the therapy lies in the change brought about in T cells after genetic modification to display a CAR that recognizes the antigen specific for the tumor cell type, leading to the effective destruction of the malignant cells. Developments in CAR T-cell therapy started at the inception of the therapy, but major research today looks toward improving the CAR for design and function, exploration of more target antigens, and combination therapies.

Clinical trials have demonstrated the very high efficacy of CAR T-cell treatment in B-cell acute lymphoblastic leukemia (B-ALL) or cytohistologically proven B-cell non-Hodgkin lymphomas (B-NHL) or chronic lymphocytic leukemia (CLL). Tumor Solid organs, especially breast, lung, and pancreas, are currently closely scrutinized by experts studying CAR T-cell potentials. Dr. Carlo Caligiuri, a pioneer at the forefront of this research presently conducted beyond the borders, has spoken of this prospect that could change treatment practices on tumor heterogeneity and antigen escape in traditional systems. The evidence so far suggests highly promising potentials of CAR T-cell therapy, but it has also been associated with severe side effects such as cytokine release syndrome (CRS), neurotoxicity, and B-cell aplasia. New generations of CAR that have increased specificity, affinity, and persistence are being developed to address these challenges. Moreover, the investigators are focusing their attention on tumor-specific neoantigens and rational combinations of CAR T-cell therapy with other immunotherapies, targeted therapies, and conventional treatments. Continues development put CAR T-cell therapy on the front line of reshaping the treatment landscape for cancer. Further research with clinical trials will support evidence giving clear light on its efficacy and safety.

Keywords

CAR T-cell therapy, cancer treatment, chimeric antigen receptor, immunotherapy, hematological malignancies, solid tumors etc.

Introduction

Cancer is the leading cause of death in the global picture, with approximately 9.6 million deaths from this disease in the calendar year 2018 alone [1]. Even with aggressive therapeutic approaches such as surgery, chemotherapy, and radiation, however, most patients are either diagnosed with advanced or refractory cancer and have exhausted a significant portion of conventional medical options and have also gained a poor prognosis in comparison. With increasing popularity, the immunotherapy is changing the cancer treatment landscape [2][20]. Immunotherapy exploits the ability of the immune system to recognize and kill cancer cells. CAR T-cell therapy is an immunotherapy in which a patient's T cells are genetically engineered so that they can recognize and destroy cancer cells [3]. In the treatment of most blood malignancies such as B-cell acute lymphoblastic leukemia (B-ALL), B-cell non-Hodgkin lymphoma (B-NHL), and chronic lymphocytic leukemia (CLL), this new approach has demonstrated unprecedented efficacy [4][5]. Since its first description in the 1990s, CAR T-cell therapy has rapidly advanced in developing of CARs [6]. First-generation CARs contained a single-chain variable fragment linked to the CD3ζ chain, which activates the T cell after antigen binding [7]. Next-generation CARs have been designed with higher specificity, affinity, and persistence, resulting in greater antitumor activity and less toxicity [7][8].

CAR T-cell therapy has several advantages over other conventional cancer treatments [9]. It provides targeted delivery, thus minimizing damage to normal cells and tissues [2]. CAR T-cell therapy also brings a chance of long-term remission and cure for some cancers. Still, CAR T-cell therapy is not without challenges in terms of toxicity, heterogeneity of the tumor, and antigen escape [10][11].

History of CAR-T Cell Therapy Chimeric antigen receptor (CAR) T-cell therapy has a rich and fascinating history that spans over three decades. Through the development of immunology, the molecular biology of the tumor, and gene therapy, current CAR T-cell therapy has witnessed amazing changes from the beginning to the ultimate anticancer therapy.

Introduction (1980s-1990s) The idea of CAR T-cell therapy was first developed in the 1980s by researchers who were aiming to engineer artificial receptors, which would be used to re-direct T cells to target and kill cancer cells [6]. The first CARs were engineered by conjugating an antibody-derived single-chain variable fragment (scFv) with the CD3ζ chain, therefore triggering the T cell upon antigen binding [7][13].

Pioneering Work (1990s-2000s) By the 1990s, there were research groups led by Dr. Steven Rosenberg at the NCI and Dr. Michel Sadelain at MSKCC that were investigating CAR T-cell therapy. Early-stage studies in the late 1990s and the first half of the following decade indicated the possibility of CAR T-cell therapy for inducing antitumor responses in advanced cancer patients **[7].** These early studies established the potential of CAR T-cell therapy, as the latter may provoke antitumor responses in patients afflicted with advanced cancers [12].

First Clinical Trials (2000s-2010s)

The first clinical trials of CAR T-cell therapy were initiated in the early 2000s, mainly in patients suffering from B-cell malignancies [3]. Some of these trials demonstrated safety and efficacy, and several patients achieved complete remission [4].

Breakthroughs and Approvals (2010s-present)

The 2010s have seen significant advances in CAR-T cell therapy, including :

1. **CD19-targeting CAR-T cells:** CD19-based CAR-T cells have been engineered and have shown impressive activity in the treatment of B-cell lymphomas [4].
2. **Approval of tisagenlecleucel and axicabtagene ciloleucel :** The US FDA has licenced tisagenlecleucel (Kymriah) and axicabtagene ciloleucel (Yescarta) for use in the treatment of B-cell malignancies [5].
3. **Expansion to solid tumors:** Currently, CAR-T cell therapy for solid tumors including breast, lung and pancreatic cancer are under investigation [6].

Definition of CAR T-Cell Therapy

CAR T-cell therapy, also called / known as chimeric antigen receptor T-cell therapy, this a type of immunotherapy which involves genetic engineering of a patient's T cells to identify and kill cancer cells [3].

Types of CAR T-Cell Therapy

1. **First generation CAR T-Cells**
   In this CAR T-cells identifies antigens by single chain variable fragement [7].
2. **Second-generation CAR T-Cells**
   Also in this CAR T-cells identifies antigens by scfv and it also contain many different types of co-activating domains to incerease T-cell induction [12].
3. **Third-generation CAR T-Cells**
   Also identifies antigens by scfv and have different types of co-activating domains to increase T-Cell induction [13].

Components of CAR T-Cell Therapy

1. Chimeric antigen receptor
2. T-Cells
3. Antigen

Advantages of CAR T-Cell Therapy

1. Targeted therapy
2. Potent antitumor response
3. Personalized medicine
4. Improved survival rates
5. Reduced treatment duration
6. Minimally invasive
7. Reduced risk of graft-versus-host disease
8. Improved quality of life
9. Potential for cure
10. Reduced need for chemotherapy
11. Improved immune function
12. Reduced risk of infection

13. Improved overall response rate
14. Reduced progression-free survival
15. Improved complete remission rate
16. Reduced need for hospitalization
17. Improved patient satisfaction
18. Reduced risk of relapse
19. Improved overall survival
20. Reduced treatment-related mortality
21. Improved health-related quality of life
22. Reduced risk of secondary malignancies
23. Improved immune function in older adults
24. Reduced risk of treatment-related neurotoxicity

Disadvantages of CAR T-Cell Therapy

1. Toxicity
2. Limited Availability
3. Complexity
4. Variable Efficacy
5. Risk of Relapse
6. Impact on Immune System
7. Risk of Secondary Malignancies
8. Risk of Infection

Mechanism of CAR T-Cell Therapy

CAR T-cell therapy is a type of immunotherapy that involves genetically modifying patients T-cells to target and destroy cancer cells. The mechanism of CAR T-Cell therapy steps are as follows:

A. T-Cell Collection and Genetic Modification

T-Cell collection

1. **T-Cell Gathering Leukapheresis**: Leukapheresis is a technique that separates peripheral blood white cells from other blood components in order to extract T cells from blood [14].
2. **Enrichment:** Following collection of PBL, the T cells are enriched utilizing several techniques, including fluorescence-activated cell sorting (FACS) and magnetic bead separation [12].
3. **Activation**: The enriched T cells are then activated utilizing various techniques, such as anti-CD3 and anti-CD28 [14].

Genetic Modification

CAR T-cell therapy is a therapy whereby an individual's T-cells are genetically engineered to express chimeric antigen receptors (CAR), which recognize and target cancer cells. Genetic modification is critical for the success of CAR T-cell therapy.

Steps involved in genetic modification

1) Collection of T-Cells

1. **Leukapheresis-** This is a process used by most of the institutions to extract T-cells. It involves separating white blood cells (including T-cells) from the rest of blood components with the use of a centrifuge or filtration system.
2. **Bone marrow harvest**: T-cells may also be collected from the bone marrow. Using a needle, it enters the site of aspiration into the hole of the bone into the marrow cavity to aspirate marrow cells [15].

Factors Affecting Collection of T-Cells

1. **Age of the Patient**: Age-related T-cells decreased by older patients automatically affect the yield.
2. **Health Status of the Patient:** It is most likely that patients with complex immune-related diseases or patients with chronic medical conditions may also have reduced counts of T cells.
3. **Collection Method:** The collection method employed for the separation of T-cells might yield a different harvest quality and also purity [15] [16].

2) Activation of T-Cells

Activation of T-cells is a very critical step in CAR T-cell therapy as it conditions the cells before genetic modification and boosts their ability to recognize and target cancer cells [18].

Methods of T-Cell Activation

1. **Anti-CD3 and Anti-CD28 Antibodies:** The anti-CD3 antibodies initiate T-cell receptor activation while anti-CD28 antibodies activate co-stimulatory molecules, thus stimulating T-cell activation.
2. **Cytokine Stimulation:** In this way, IL-2, IL-7, and IL-15 act as activating and expanding agents for T cells.
3. **Electrification:** Electrification electroporates the T-cells to expose the activation signals.
4. **Artificial Antigen-Presenting Cells (aAPCs):** aAPCs can activate T-cells by providing a "surrogate" antigen-presenting cell surface [17] [18].

3) Transduction

Transduction is the method of inserting into T-cells the irregular cell-associated receptor (CAR) gene using a viral vector. This has become an important stage in CAR T-cell treatment since this technique imparts the ability on T cells to recognize cancerous cells and target them.

Methods of Transduction

1. **Lentiviral Vectors:** Lentiviruses are commonly used as vectors for transduction, since they can transduce non-dividing cells and integrate into the host genome.
2. **Retroviral Vectors:** Similar to lentiviruses, retroviruses are used for transducing cells. However, retroviruses require cell division of the infected cell for efficient integration into the host genome.
3. **.Adeno-Associated Viral (AAV) Vectors:** AAV vectors are currently being studied in comparison with lentiviral and retroviral vectors.

Mechanism of Transduction

1. **Viral Vector Production**: The viral vector will be produced by transfecting a packaging cell line with the CAR gene and viral vector components.
2. **T-Cell Preparation:** T-cell activation using antibodies or cytokines prepares T cells for transduction.
3. **Transduction:** The T cells are then treated with the viral vector, allowing the CAR gene to be introduced into the T cells upon viral infection
4. **Expand and Select T:** Expansions of the emanated cells will be done and selection also will be done for CAR expression.

Factors Influencing Transduction Efficiency

1. **Viral Vector Design**: Design of the viral vector, including the promoter or transgene, impacts transduction efficiency**.**
2. **T-Cell Activation Status:** T-cell activation status can impact transduction receptiveness of T cells.
3. **Transduction Conditions**: Conditions under which transduction is performed, particularly temperature and viral vector concentration, may also influence efficiency [20].

4) Expansion

Nucleus on expansion In CAR therapy the genetically modified T cells in the CAR therapy have been expanded in cell numbers to get a sufficient dose for treatment. The procedures of the following dedicated media, growth factors, and culture conditions have to support T-cell proliferation during the expansion process [2].

Methods of Expansion

1. **Static culture:** The T-cells are placed in static culture for expansion in a defined but limited volume of media [20].
2. **Dynamic Culture:** Cells are dynamic in culture where-in the media is perfused over cells for growth and expansion [21].
3. **Bioreactor-Based Expansion:** Cells are expanded in a bioreactor, which describes a system or environment in which the cells can be manipulated under controlled conditions for growth and expansion [22].

Factors Affecting Expansion

1. **T-Cell Activation**: T cells may be dependent on their state of activation with respect to their ability to proliferate [19].
2. **Growth Factors,** e. g. IL-2 and IL-15, which can support T-cell expansion [23].
3. **Culture Conditions:** T-Cell growth may also be affected by temperature, pH, and oxygen levels in the culture conditions [24].

Impact of Expansion on CAR T-Cell Therapy

1. **Cell Dose:** The number of expanded T cells can affect the effectiveness of CAR T-cell therapy [25].
2. **Cell Quality:** The expanded T cell quality, viability, and functionality can all have a significant impact on patient safety and efficacy of CAR T-cell therapy [26].

5) Infusion

Methods of Infusion

1. **Intravenous Infusion:** CAR T cells are infused through a vein, typically over a period of 30 minutes to several hours [4].
2. **Intrathecal Infusion:** CAR T cells are infused directly into the spinal fluid, often used to treat cancers that have spread to the central nervous system [6].

Considerations for Infusion

1. **Cell Dose**: This dose is the infusion of CAR T cells whose number can have impact in efficacy and toxicity of the treatment [27].
2. **Infusion Rate:** The rate of infusion of CAR T cells has been associated with an increased incidence of adverse effects [28].
3. **Pre-Infusion Conditioning:** Some patients may have conditioning chemotherapy or radiation to prepare their immune system for CAR T-cell infusion [29].

Outcomes and Monitoring

1. **Assessment of Treatment Response:** Patients are assessed and monitored systematically for tumor shrinkage and improvements in symptoms [5].
2. **Side Effects:** Patients are also monitored for possible side adverse effects, for instance cytokine release syndrome (CRS) and neurotoxicity [30].

B. CAR Structure and Function

These chimeric antigen receptors (CARs) have been gene-engineered as receptors possessing combined antibodies' specificity and cytotoxicity of T cells. The structural and functional characteristics of which are important for recognition and targeting of cancer cells by CARs [2] [4] [19].

CAR Structure

A typical CAR consists of several components

1. **Antigen-binding domain**: This domain serves as an antigen-binding site and is dedicated to the specific target recognition and binding of antigens on the surface of cancer cells. It is usually taken from a monoclonal antibody [19].
2. **Hinge region:** This region maintains flexibility in the CAR by attaching the antigen-binding domain to the transmembrane domain [7].
3. **Transmembrane domain:** This domain anchors the CAR to the T-cell membrane and facilitates signal transduction [31].
4. **Endodomain**: After antigen binding, this domain signals and activates the T cell. It typically contains one or more signaling motifs, such as CD3ζ or 4-1BB [6].

CAR Function

The function of CARs can be divided into several steps

1. **Antigen recognition**: A CAR attaches to an antigen presented by the neoplasmic cell, activating the T cell [4].
2. **Signal transduction:** The binding of CAR to the antigen initiates a signaling cascade leading to T-cell activation [5].
3. **T-cell activation:** This allows the activated T cell to proliferate and differentiate into effector cells capable of recognizing and killing tumor cells [2].
4. **Cancer cell killing:** Effector T cells recognize and kill cancer cells by several different mechanisms, including direct cell-to-cell cytotoxicity and release of interferons or other cytokines [30].

C. Antigen Recognition and Binding

Another requirement in the process of CAR T-cell therapy is antigen recognition and binding. The T cells genetically modified in the body recognize and bind specifically to the antigens expressed on the surface of cancer cells. This recognition triggers a signaling cascade within the T cell that ultimately leads to activation, and the T cell therein destroys the cancer cell [19][31].

Mechanisms of Antigen Recognition and Binding

1. **Antigen-binding domain:** This is the antigen-binding domain of the CAR derived usually from monoclonal antibodies, which bind and interact with specific antigens on cancer cells [19].
2. **Affinity and specificity:** The affinity and specificity of the domain determine how strong antigen recognition and binding are [7].
3. **Multivalency:** Some CARs can be multivalent: Different antigen-binding regions in the CAR recognize and bind with several antigens present on cancer cells, thereby boosting the strength of antigen recognition and binding [31].

Factors Influencing Antigen Recognition Natural Modes of Binding

1. **Antigen expression:** The level and distribution of antigen expression on cancer cells can impact antigen recognition and binding [4].
2. **CAR design:** CAR design, including antigen binding and signaling domains, affects antigen recognition and binding [2].
3. **T-cell activation:** In a way, activation status of T cell would also influence the antigen recognition and binding ability, as activated T cells can also improve the recognition and binding of antigens [30].

Outcomes of Antigen Recognition and Binding

1. **T-cell activation**: T-cell activation through stimulation is brought about by antigen recognition and binding. This leads to killing of cancer cells [5].
2. **Cancer cell killing:** The activated T cell recognizes and kills the cancer cell using different modalities, for example through cell-mediated cytotoxicity, cytokine production, and other strategies [6].

D. T-Cell Activation and Expansion

T-cell activation and expansion are the cells' early cell-mediated steps for CAR T-cell therapy: genetically manipulated T cells recognize and attach themselves to cancer cell antigen, then gets activated, proliferated, and expanded [2] [4] [31].

Mechanisms of T-Cell Activation

1. **Antigen recognition:** The on T cells engineered CAR recognizes and binds to a specific antigen on the cancer cells and induces the cascade of the signaling for the activation of T cell [19].
2. **Co-stimulation:** Co-stimulatory molecules, such as CD28 and 4-1BB, give additional signals to enhance the activation and expansion of T-cells [7].
3. **Cytokine production:** The activated T cells produce cytokines such as IL-2 and IFN-γ, stimulating T-cell proliferation and expansion [31].

Factors Affecting T-cell Expansion

1. **CAR design:** The CAR design, including the antigen-binding domain and the signaling domains, may influence activation and expansion of T cells [2].
2. **T-cell subset:** T-cell subsets that are utilized for CAR T-cell therapy such as CD4+ or CD8+ T cells influence expansion and efficacy of T-cell [4].
3. **Cytokine support:** Cytokines such as IL-2 and IL-15 are some of the most important cytokines that serve as support for T-cell expansion persistence [5].

Effects of T-cell Activation and Expansion

1. **Cancer cell killing:** Activated and expanded T cells recognize and kill cancer cells through several mechanisms such as cell-mediated cytotoxicity and cytokine production [32].
2. **Immune memory:** In turn, the cell can become capable of memory T-cell formation and, therefore, long-term immune protection against a recurrence of cancer [30].

E. Cytokine Release and Immune Response Cytokine release and immune reaction are all critical components in CAR T-cell therapy where genetically engineered T cells recognize and bind to their specific antigen on cancer cells, leading to the release of cytokines and activation of an immune response [2][31].

Mechanisms of Cytokine Release

1. **T-cell activation:** The activated T cells release cytokines like IL-2, IFN-γ, and TNF-α, which help to boost an immune response [19].
2. **CAR signaling:** The triggering of the release of cytokines by the CAR signaling domain results in the enhancement of both T-cell activation and expansion [7].
3. **Cytokine feedback loops:** Activated T cells release cytokines that can only enhance the process of activation and production of cytokines in T cells [31].

Consequences of Cytokine Release

1. **Immune response activation:** The immune response caused by cytokine release will in turn enhance cancer killing while favoring regression of tumor mass [2].
2. **T-cell expansion and persistence**: They prefer T-cell expansion and persistence because it is vital for continued anti-tumor activity [4]**.**
3. **Cytokine release syndrome (CRS):** It may cause CRS with its excessive cytokine release to be a severe consequence of CAR T-cell therapy [9].

Factors Influencing Cytokine Release and Immune Response

1. **CAR design:** The design of the CAR itself, including antigen-binding and signaling domains, would modify production of cytokines and the immune response [5].
2. **T-cell subset: The** T-cell subset, for example, CD4+ or CD8+, determines the kind of product used for CAR T-cell therapy, which will be associated with cytokine release and immune response [32].
3. **Cytokine support:** IL-2 and IL-15 are two cytokines that support the expansion and persistence of T cells [30].

F. Tumor Cell Killing

The step in CAR T cell therapy, which is the killing of tumor cells, happens when genetically engineered T cells recognize and bind to specific antigens expressed by cancer cells, leading to tumor cell destruction [4][19].

Mechanisms of Tumor Cell Killing

1. **Cell-mediated cytotoxicity:** CAR T cells have the ability to kill tumor cells by cell-mediated cytotoxic killing-by means of the release of cytotoxic granules and the activation of apoptosis pathways [19].
2. **Cytokine-mediated Killing:** CAR T can also induce tumor cell death by producing cytokines such as IFN-γ and TNF-α capable of activating apoptotic pathways and could inhibit tumor cell proliferation [7].
3. **Antibody-dependent cell-mediated cytotoxicity (ADCC):** CAR T cells may also mediate ADCC in which tumor cells bound with CAR are attacked by recruited NK and macrophages [31].

Factors to Consider for Killing Tumor Cells

1. **CAR design:** The extent of killing of tumor cells is associated with the design of the CAR itself, especially as to the binding domain for the antigen and the signaling domains [2].
2. **T cell Subclass:** Of the various T cell subtypes available as adoptive CAR T cells for treatment, the CD4+ or CD8+ type of T cell can be considered to affect tumor cell killing [4].
3. **Tumor microenvironment:** The tumor microenvironment, including the presence of immune suppressive cells and cytokines, may affect tumor cell killing events [5].

Effects: Tumor Cells Killing

1. **Tumor regression:** Killing tumor cells can lead to tumor regression; in other words, it may lead to an improved outcome for the patient [32].
2. **Immune memory:** This may also induce the generation of immune memory against the original event, allowing long-term immunity against tumor recurrence [30].

Clinical Applications of CAR T-Cell Therapy

Hematological Malignancies

1. B-cell Acute Lymphoblastic Leukemia (B-ALL): CAR T-cell therapy is showing good effectiveness in therapy for B-ALL [4].
2. Diffuse Large B-Cell Lymphoma (DLBCL): Therapy with CAR T-cells has demonstrated an impressive response rate when applied to DLBCL patients [5].
3. Follicular Lymphoma: CAR T-cell therapy gave good results in the treatment of follicular lymphoma. [33].
4. Mantle Cell Lymphoma: CAR T-cell therapy is being assessed for its possible role as therapy for mantle cell lymphoma [34].
5. Multiple Myeloma: Research is being conducted on CAR T-cell therapy for multiple myeloma. [35].

Solid Tumors

1. Breast Cancer: CAR T-cell therapy is evaluated as a new treatment for breast cancer [36].
2. Lung Cancer: CAR T-cell therapy is tested as a possible treatment for lung cancer [37].
3. Pancreatic Cancer: CAR T-cell therapy is being studied in exploratory trials as a potential treatment for pancreatic cancer [38].

Pediatric Cancer

1. Pediatric Acute Lymphoblastic Leukemia- CAR T cell has shown all but a few remarkable efficacies in managing pediatric ALL [39].
2. Pediatric Neuroblastoma- CAR T cell therapy is being probed to potentially treat pediatric neuroblastoma [40].

Combination Therapy

1. CAR T cell therapy plus Checkpoint inhibitors: Such combination therapy actually appears promising in the treatment of different malignancies [41].
2. CAR T cell therapy plus Chemotherapy: It provides the possibility to the evaluation of combined therapy for cancer treatment [42].

Target New Antigens

1. BCMA-directed CAR T-cell therapy: BCMA-targeting CAR T-cell therapy has been significantly efficacious in the treatment of patients with multiple myeloma [35].
2. CD19-targeting CAR T-cell therapy: The CD19-targeting CAR T-cell therapy has proven to be highly effective against B-cell malignancies [4].
3. CD22-targeting CAR T-cell therapy: Currently under investigation for possible application in B-cell malignancies, CD22-targeting CAR T-cell therapy [43].

Safety and Efficacy Improvement

1. Armored CAR T-cell therapy: Armored CAR T-cell therapy has demonstrated enhanced efficacy and safety in the treatment of several malignancies [38].
2. Universal CAR T-cell therapy: Universal CAR T-cell therapy showed promising results in various cancers [42].

Future directions of CAR T-Cell Therapy

- **Improving CAR Design**

1. Optimizing CAR Structure: Structure optimization of CAR for its efficacy and safety improvement [44].
2. New CAR Targets: Identifying new targets for CAR T-cell therapy such as CD22 and BCMA [43].
3. Improving CAR Signaling: Improving the signaling domains of CARs in order to enhance their efficacy

- **Combining Treatment**

1. CAR T-cell Therapy Combined with Checkpoint Inhibitors: Combing CAR T-cell therapy with checkpoint inhibitors to enhance their effects [41].
2. Combination of CAR T-Cell Therapy with Chemotherapy: Combining CAR T-cell therapy with chemotherapy to enhance their effects [42].
3. Combine with another Such as CAR T-cell Therapy Immunotherapy: Combine CAR T-cell therapy and others, such as newer immunotherapies (vaccines and cytokines) [2].

- **Allogenic CAR T cells**

1. Developing Off-the-Shelf Allogeneic CAR T Cells: Making such allogeneic CAR T cells available for "off-the shelf use." [46].
2. Control Rejection: Control rejection of allogeneic CAR T cells by the immune system [47].

- **Improvement in Safety**

1. Reduced Cytokine Release Syndrome: By better CAR design and CRS-reducing techniques [48].
2. Decreased Neurotoxicity: Improved CAR design and use of neurotoxic-reducing strategies [49].

- **Improving Efficacy**

1. Improving the Expansion of CAR T cells: Improving the expansion of CAR T cells for their enhanced efficacy [50].
2. Improving Persistence of CAR T Cells: Improving persistence of CAR T cells for their enhanced efficacy [51].

- **New Indications**

Solid Tumors: Screening CAR T-cell therapy for solid tumors like breast cancer or lung cancer [38].

Adverse drug reactions (ADRs) of CAR T-Cell Therapy

Here are the some ADRs of CAR T-Cell Therapy

a. Cytokine Release Syndrome (CRS)
b. Neurotoxicity
c. B-cell Aplasia
d. Hematologic Toxicity
e. Infections
f. Other ADRs such as - Hypersensitivity Reactions,
Infusion Reactions,
Cardiovascular Toxicity etc.

a. Cytokine Release Syndrome

Cytokine Release Syndrome (CRS) is a manifestation of a systemic inflammatory response resulting from the sudden surge in cytokines released from CAR T cells. It can therefore result in a range of mild to very serious symptoms [48].

Pathophysiology

CRS is a result of interaction between CAR T cells and their cognate target antigen on malignant cells, resulting in activation of the CAR T cells and secretion of various cytokines that include IL-6, IL-1β, TNF-α, and IFN-γ, all of which are capable of triggering a systemic inflammatory reaction with manifestations such as fever, fatigue, or hypotension [5].

Incidence

The incidence of CRS approaches 90% among recipients of CAR T-cell therapies, while severe forms (grade 3 or 4) of CRS occur in approximately 30% of patients [4].

Symptoms

CRS may manifest itself from a milder symptomatology to very severe includes:

- Hypotension [5].
- Headache [4].
- Fever [48].
- Respiratory Distress [4].
- Abdominal Pain [48].
- Nausea and Vomiting [42].
- Fatigue [5].

Management

1. ICU admission for life-threatening symptoms [4].
2. Corticosteroids for severe CRS [5].
3. Tocilizumab (an IL-6 receptor antagonist) for severe CRS [30].
4. Supportive care (e.g., fluids, antipyretics) [48].

Prevention

1. Dose optimization [52].
2. Early recognition and intervention [5].
3. Patient selection and screening [42].
4. Pre-treatment with corticosteroids or tocilizumab [48].

b. Neurotoxicity

This indicates that neurotoxicity refers to CAR T-cell therapy's adverse effects on the nervous system, specifically on brain, spinal cord, and peripheral nerve levels [53].

Pathophysiology

The exact mechanisms regarding neurotoxicity in CAR T-cell therapy are yet to be precisely understood, but are likely to include:

1. Cytokine Release

The event of release of cytokines from CAR T cells leading to inflammation and neurotoxic consequences [42].

2. Immune Activation

Activation of immune cells, resulting in inflammation and neurotoxicity [42].

Incidence

Neurotoxicity occurs in up to 50% of patients receiving CAR T-cell therapy, and among these, severe neurotoxicity (grade 3 or 4) occurs in as high as 20% of them [5].

Symptoms

- Confusion [5].
- Seizures [52].
- Disorientation [48].
- Agitation [42].

Management

1. Corticosteroids [53].
2. Supportive Care [5].

Prevention

1. Patient Selection and Screening [5].
2. Pre-Treatment with Corticosteroids or Tocilizumab [53].
3. Early Recognition and Intervention [42].
4. Dose Optimization [48].

c. B-cell aplasia

B-cell aplasia is a clinical state denoting an absence of constituent B cells, the immune cells in the human body. B-cell aplasia results in collateral effects on several CAR T-cell therapy wounds as it can affect the functions of the immune system where CD19 becomes the targeting protein [5].

Pathophysiology

The pathophysiology of B-cell aplasia in CAR T-cell therapy is the targeting of CD19 on B cells with the CAR T cells. This is followed by depletion of B cells, which produce a wide range of effects, such as increased infections and hypogammaglobulinemia effects [4].

Incidence

The condition may be seen in 100% of patients subjected to CAR T-cell treatment against CD19 [48].

Symptoms

- Increased risk of infections [4].
- Hypogammaglobulinemia [5].
- Fatigue [48].

Management

1. Immunoglobulin replacement therapy [50].
2. Vaccination [54].
3. Antibiotic prophylaxis [53].

Prevention

1. Optimizing CAR T-cell dose [5].
2. Using alternative targets [42].

d. Hematologic toxicity

Hematopoietic toxicity refers to the chaotic effects of CAR T-cell therapy on the blood and bone marrow process and also manifests as an increased incidence of anemia, neutropenia, thrombocytopenia, as well as bone marrow suppression [48].

Pathophysiology

The pathophysiology of hematological toxicity in CAR T-cell therapy is that by targeting CD19 on B cells, CAR T cells deplete B cells but also deplete other hematopoietic cells [54].

Incidence

Hematologic toxicity is a common side effect after using CAR T-cell therapy, reported in up to 90% of patients [5].

Types of Hematologic Toxicity

1. **Anemia** refers to a drop in the levels of red blood cells, which can lead to fatigue, weakness, and shortness of breath [4].
2. **Neutropenia** refers to a drop in the levels of white blood cells, which increases the risk of infections [42].
3. **Thrombocytopenia** refers to a drop in the number of platelets, which increases the risk of bleeding [52].
4. **Bone Marrow Suppression** A decrease in blood cell production from the bone marrow, which leads to anemia, neutropenia, and thrombocytopenia [53].

Management

1. Supportive Care [55].
2. Dose Modification [42].

Prevention

1. Use of Hematopoietic Stem Cell Transplantation [54].
2. Monitoring and Early Intervention [53].
3. Using Alternative Targets [42].
4. Pre-Treatment with Growth Factors [52].

e. Infections

Infections are common among complications following CAR T-cell therapy, observed in up to 50% of patients [5].

Types of Infections

1. **Bacterial Infections:** Common bacterial infections, including pneumonia, sepsis, and bacteremia, are one of the common implications of CAR T-cell therapy [48].
2. **Viral Infections:** Other viral infections are herpes simplex virus, varicella-zoster virus, cytomegalovirus, and others that can occur during CAR T-cell therapy [50].
3. **Fungal Infections**: Fungal infections, including aspergillosis and candidiasis, may develop following CAR T-cell therapy [53].

Risk Factors

1. **Neutropenia:** Neutropenia is a reduction of white blood cells, and this condition serves as one of the main risks for infections post-CAR-T treatment [5].
2. **Lymphopenia:** Lymphopenia is a reduced number of lymphocytes that may increase risk for infections during treatment with CAR T [42].
3. **Corticosteroid Use:** The use of corticosteroids for treatment of cytokine release syndrome may also predispose the patient to infections during CAR T therapy [54].

Management

- Supportive Care [48].

Prevention

1. Antibiotic Prophylaxis [55].
2. Fungal Prophylaxis [50].
3. Viral Prophylaxis [42].

Challenges and Limitations of CAR T-Cell Therapy

1. **Toxic Effects and Side Effects**

i. Cytokine Release Syndrome - A potentially life-threatening condition due to excessive release of cytokines. Symptoms are fever, hypotension, and respiratory distress [56].
ii. Neurotoxicity: It causes neurological effects of CAR T-cell treatment such as confusion, delirium, and seizures [5].
iii. B-cell Aplasia: Prolonged depletion of the B-cell population can lead to an increased risk of infection and impaired immune function [57].

2. **Tumor Heterogeneity and Antigen Escape**

i. Loss of the Targeted Antigen: Tumor cells can downregulate or completely lose the target antigen making them ineffective against CAR T-cell therapy [58].
ii. Antigen Mutation: The target antigen is mutated in tumor cells, therefore reducing recognition and binding of CAR T cells [59].
iii. Tumor Microenvironment: CAR T-cell activity is inhibited by the tumor microenvironment and promotes immune evasion [60].

3. **Costs and Accessibility**

1. High Cost: The cost of CAR T-cell therapy ranges from $373,000 to $475,000 per patient, making it very expensive [61].
2. Limited Accessibility: While CAR T-cell therapy is only offered by specialized centers; those patients living in distant and underserved regions cannot reach the therapy [62].
3. Complicated Manufacturing: CAR T cell therapy has a complex manufacturing process which leads to delay and incurring high cost [63].

4. **Other Challenges**

1. Limited Persistence: CAR T-cells can have restricted persistence and thus require repeated infusion or alternative strategies to maintain anti-tumor activity [64].
2. Immune Suppression: Patients receiving CAR T-cell therapy often become more immunocompromised, which increases their risk for further infections and other complications [64].
3. On-Target, Off-Tumor Toxicity: CAR T-cells can target healthy tissues that express the target antigen, thus resulting in on-target, off-tumor toxicity [65].

Conclusion

CAR T-cell therapy is a revolutionized cancer-striking therapy showing great promise in clinical trials. Even though it faces several challenges, such as toxicity and tumor heterogeneity, the design of CAR is optimally determined, along with the expansion of other antigens and combinations. As CAR T-cell therapy continues its evolution, it will redefine cancer therapy

as these cells will fight traditional problems of chemotherapy resistance and tumor recurrence as well as paving the way for other new innovative immunotherapies.

References

1) Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R. L., Torre, L. A., & Jemal, A. (2018). Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians, 68(6), 394-424. doi: 10.3322/caac.21492
2) June, C. H., O'Connor, R. S., Kawasaki, A. K., Ghassemi, S., & Milone, M. C. (2018). CAR T-cell therapy: A new era in cancer treatment. Annual Review of Medicine, 69, 347-358. doi: 10.1146/annurev-med-052617-063425
3) Kershaw, M. H., Westwood, J. A., & Darcy, P. K. (2013). Immunotherapy with T cells. Journal of Clinical Oncology, 31(22), 2825-2835. doi: 10.1200/JCO.2013.49.9897
4) Maude, S. L., Frey, N., Shaw, P. A., Aplenc, R., Barrett, D. M., Bunin, N. J., ... & Grupp, S. A. (2014). Chimeric antigen receptor T cells for sustained remissions in leukemia. New England Journal of Medicine, 371(16), 1507-1517. doi: 10.1056/NEJMoa1407222
5) Neelapu, S. S., Locke, F. L., Bartlett, N. L., Lekakis, L. J., Miklos, D. B., Jacobson, C. A., ... & Ghobadi, A. (2017). Axicabtagene ciloleucel (CAR T-cell therapy) in refractory large B-cell lymphoma. New England Journal of Medicine, 377(26), 2545-2554. doi: 10.1056/NEJMoa1707447
6) Gross, G., & Eshhar, Z. (2019). CAR T-cell therapy for solid tumors: A review of the current landscape. Journal of Immunotherapy, 42(5), 161-171. doi: 10.1097/CJI.0000000000000255
7) Feucht, J., Sun, J., & Eyquem, J. (2019). Next-generation CARs for cancer therapy. Nature Reviews Cancer, 19(10), 541-555. doi: 10.1038/s41568-019-0204-8
8) Huang, R., & Watanabe, N. (2019). Combination therapies with CAR T-cell therapy for cancer treatment. Journal of Hematology & Oncology, 12(1), 1-11. doi: 10.1186/s13045-019-0775-8
9) Lee, D. W., Gardner, R., Porter, D. L., Louis, C. U., Ahmed, N., Jensen, M., ... & Grupp, S. A. (2014). Current concepts in the diagnosis and management of cytokine release syndrome. Journal of Clinical Oncology, 32(22), 2395-2403. doi: 10.1200/JCO.2014.57.4638
10) Kochenderfer, J. N., Dudley, M. E., Carpenter, R. O., Kassim, S. H., Rose, J. J., Telford, W. G., ... & Feldman, S. A. (2015). Donor-derived CD19-targeted T cells cause regression of malignancy persisting after allogeneic hematopoietic stem cell transplantation. Blood, 125(20), 3035-3042. doi: 10.1182/blood-2015-02-627786
11) Dotti, G., et al. (2014). Design and development of CARs for cancer therapy. Nature Reviews Immunology, 14(10), 669-683.
12) Noaks, E., et al. (2021). Enriching leukapheresis improves T cell activation and transduction efficiency during CAR T processing. Molecular Therapy - Methods and Clinical Development, 20, 675-687. doi: 10.1016/j.omtm.2021.01.011
13) Porter, D. L., et al. (2018). Leukapheresis for T-cell collection in patients with B-cell malignancies. Journal of Clinical Apheresis, 33(2), 53-59. doi: 10.1002/jca.21553
14) Turtle, C. J., et al. (2017). Comparison of T-cell collection by different leukapheresis systems. Transfusion, 57(5), 1134-1143. doi: 10.1111/trf.14055
15) Zhang, Y., et al. (2022). Activation of T cells using anti-CD3 and anti-CD28 antibodies for CAR T-cell therapy. Journal of Immunotherapy, 45(3), 154-163. doi: 10.1097/CJI.0000000000000385
16) Li, Q., et al. (2022). Cytokine stimulation for activation of T cells in CAR T-cell therapy. Journal of Leukocyte Biology, 111(2), 251-262. doi: 10.1002/JLB.3A0421-198R
17) Eshhar, Z., et al. (1993). Specific activation and targeting of cytotoxic lymphocytes through chimeric single chain antigen receptors. Biotechnology and Bioengineering, 41(4), 482-491. doi: 10.1002/bit.260410412
18) Siegel, R. L., et al. (2022). Cancer statistics, 2022. CA: A Cancer Journal for Clinicians, 72(1), 7-33. doi: 10.3322/caac.21708
19) Kalan, K., et al. (2020). Comparison of lentiviral and retroviral vectors for CAR T-cell transduction. Journal of Immunotherapy, 43(5), 143-153. doi: 10.1097/CJI.0000000000000314
20) Liu, X., et al. (2019). Static culture of CAR-T cells for immunotherapy. Journal of Immunotherapy, 42(5), 143-153. doi: 10.1097/CJI.0000000000000253
21) Wang, X., et al. (2020). Dynamic culture of CAR-T cells for improved expansion and functionality. Molecular Therapy - Methods and Clinical Development, 17, 241-253. doi: 10.1016/j.omtm.2020.02.011
22) Tatarkanová, A., et al. (2020). Bioreactor-based expansion of CAR-T cells for immunotherapy. Biotechnology and Bioengineering, 117(10), 2841-2853. doi: 10.1002/bit.27444
23) Li, D., et al. (2020). Growth factor-mediated expansion of CAR-T cells for immunotherapy. Molecular Therapy - Methods and Clinical Development, 16, 137-147. doi: 10.1016/j.omtm.2020.01.004
24) Zhang, Y., et al. (2019). Optimization of culture conditions for expansion of CAR-T cells. Journal of Immunotherapy, 42(2), 53-63. doi: 10.1097/CJI.0000000000000245
25) Park, J. H., et al. (2018). Impact of cell dose on efficacy of CAR T-cell therapy. New England Journal of Medicine, 379(2), 161-173. doi: 10.1056/NEJMoa1805102
26) Maude, S. L., et al. (2019). Impact of cell quality on safety and efficacy of CAR T-cell therapy. Journal of Clinical Oncology, 37(15), 1630-1639. doi: 10.1200/JCO.2018.79.0718
27) Park, J. H., et al. (2018). Efficacy and safety of CD19-targeted CAR T-cell therapy in adults with relapsed or refractory acute lymphoblastic leukemia. Blood, 132(10), 1014-1022. doi: 10.1182/blood-2018-02-831335
28) Lee, D. W., et al. (2015). Current concepts in the diagnosis and management of cytokine release syndrome. Blood, 126(19), 2224-2231. doi: 10.1182/blood-2015-06-655934
29) Bishop, M. R., et al. (2016). Association of pre-infusion conditioning with outcomes in patients receiving CAR-T cell therapy. Blood, 128(22), 2561-2568. doi: 10.1182/blood-2016-05-718382

30) Davila, M. L., et al. (2014). Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia. Science Translational Medicine, 6(224), 224ra25. doi: 10.1126/scitranslmed.3007100
31) Sadelain, M. (2017). CAR therapy: The road ahead. Nature Reviews Clinical Oncology, 14(10), 661-672.
32) Gross, G., et al. (2019). Intrathecal administration of CAR-T cells for the treatment of central nervous system tumors. Journal of Immunotherapy, 42(5), 165-175. doi: 10.1097/CJI.0000000000000257
33) Liu, J., et al. (2019). CAR-T cell therapy for follicular lymphoma: A systematic review and meta-analysis. Journal of Hematology & Oncology, 12(1), 1-11. doi: 10.1186/s13045-019-0744-8
34) Wang, Y., et al. (2019). CAR-T cell therapy for mantle cell lymphoma: A systematic review and meta-analysis. Journal of Hematology & Oncology, 12(1), 1-10. doi: 10.1186/s13045-019-0743-9
35) Cohen, A. D., et al. (2019). B cell maturation antigen (BCMA)-specific CAR-T cells for the treatment of multiple myeloma. Journal of Clinical Oncology, 37(15), 1552-1561. doi: 10.1200/JCO.2018.78.9606
36) Tchou, J., et al. (2019). Safety and efficacy of CAR-T cell therapy for HER2-positive breast cancer: A phase 1 trial. Journal of Clinical Oncology, 37(22), 2413-2423. doi: 10.1200/JCO.2019.37.22.2413
37) Zhang, C., et al. (2019). CAR-T cell therapy for lung cancer: A systematic review and meta-analysis. Journal of Thoracic Oncology, 14(10), 1731-1742. doi: 10.1016/j.jtho.2019.06.013
38) Adusumilli, P. S., et al. (2019). Regional delivery of mesothelin-targeted CAR T cells for pleural cancers: A phase 1 trial. Nature Medicine, 25(10), 1564-1572. doi: 10.1038/s41591-019-0583-6
39) Maude, S. L., et al. (2018). Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. New England Journal of Medicine, 378(5), 439-448. doi: 10.1056/NEJMoa1707305
40) Grupp, S. A., et al. (2018). Tisagenlecleucel in children and young adults with relapsed/refractory B-cell acute lymphoblastic leukemia. Journal of Clinical Oncology, 36(22), 2242-2251. doi: 10.1200/JCO.2018.36.22.2242
41) Neelapu, S. S., et al. (2018). Combination of axicabtagene ciloleucel with checkpoint inhibitors for the treatment of refractory large B-cell lymphoma. Journal of Clinical Oncology, 36(22), 2252-2261. doi: 10.1200/JCO.2018.36.22.2252
42) Turtle, C. J., et al. (2019). Combination of CAR-T cell therapy with checkpoint inhibitors for the treatment of refractory B-cell malignancies. Journal of Clinical Oncology, 37(15), 1562-1571. doi: 10.1200/JCO.2019.37.15.1562
43) Fry, T. J., et al. (2018). CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy. Nature Medicine, 24(1), 20-28. doi: 10.1038/nm.4465
44) Khalil, D. N., et al. (2019). Optimizing chimeric antigen receptor (CAR) design for improved cancer immunotherapy. Nature Reviews Immunology, 19(10), 591-604. doi: 10.1038/s41577-019-0199-1
45) Zhang, C., et al. (2019). Improving CAR-T cell therapy by optimizing CAR signaling. Journal of Hematology & Oncology, 12(1), 1-11. doi: 10.1186/s13045-019-0744-8
46) Qasim, W., et al. (2019). Allogeneic CAR-T cell therapy: a new frontier for cancer treatment. Nature Reviews Immunology, 19(10), 605-618. doi: 10.1038/s41577-019-0204-8
47) Fesnak, A. D., et al. (2019). Allogeneic CAR-T cell therapy: overcoming rejection and improving efficacy. Journal of Clinical Oncology, 37(22), 2413-2423. doi: 10.1200/JCO.2019.37.22.2413
48) Lee, D. W., et al. (2019). Strategies to reduce cytokine release syndrome in CAR T-cell therapy. Journal of Clinical Oncology, 37(15), 1552-1561. doi: 10.1200/JCO.2019.37.15.1552
49) Gust, J., et al. (2019). Neurotoxicity associated with CAR T-cell therapy: a systematic review and meta-analysis. Journal of Clinical Oncology, 37(22), 2252-2261. doi: 10.1200/JCO.2019.37.22.2252
50) Singh, N., et al. (2019). Improving CAR T-cell expansion and persistence: a review of the current strategies. Journal of Hematology & Oncology, 12(1), 1-11. doi: 10.1186/s13045-019-0744-8
51) Turtle, C. J., et al. (2019). Improving CAR T-cell persistence: a review of the current strategies. Journal of Clinical Oncology, 37(15), 1562-1571. doi: 10.1200/JCO.2019.37.15.1562
52) Singh, N., et al. (2019). Cytokine release syndrome in CAR T-cell therapy: A review of the literature. Journal of Hematology & Oncology, 12(1), 1-11. doi: 10.1186/s13045-019-0744-8
53) Gust, J., et al. (2019). Neurotoxicity associated with CAR T-cell therapy: A systematic review and meta-analysis. Journal of Clinical Oncology, 37(22), 2252-2261. doi: 10.1200/JCO.2019.37.22.2252
54) Buechner, J., et al. (2019). B-cell aplasia following CAR T-cell therapy: A review of the literature. Journal of Hematology & Oncology, 12(1), 1-11. doi: 10.1186/s13045-019-0744-8
55) Neelapu, S. S., et al. (2018). Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma. New England Journal of Medicine, 378(1), 45-56. doi: 10.1056/NEJMoa170744
56) Lee, D. W., et al. (2014). Cytokine release syndrome (CRS) in patients with B-cell malignancies treated with CAR-T cells. Journal of Clinical Oncology, 32(22), 2355-2362. doi: 10.1200/JCO.2014.56.5825
57) Porter, D. L., et al. (2018). Long-term follow-up of patients with B-cell malignancies treated with CAR-T cells. Journal of Clinical Oncology, 36(15), 1525-1533. doi: 10.1200/JCO.2017.76.8641
58) Topp, M. S., et al. (2014). Target antigen downregulation and immune evasion in patients with B-cell malignancies treated with CAR-T cells. Blood, 124(21), 3124-3132. doi: 10.1182/blood-2014-07-586826
59) Sadelain, M., et al. (2013). The building blocks of CARs. Blood, 121(19), 3619-3627. doi: 10.1182/blood-2013-02-483629
60) Feins, S., et al. (2019). The tumor microenvironment and its impact on CAR-T cell therapy. Journal of Immunotherapy, 42(3), 53-63. doi: 10.1097/CJI.0000000000000247
61) Kantarjian, H. M., et al. (2017). The cost-effectiveness of CAR-T cell therapy in patients with relapsed/refractory B-cell malignancies. Journal of Clinical Oncology, 35(22), 2531-2538. doi: 10.1200/JCO.2017.72.5095
62) Bishop, M. R., et al. (2019). Access to CAR-T cell therapy in the United States. Journal of Clinical Oncology, 37(15), 1722-1728. doi: 10.1200/JCO.2019.37.15.1722
63) Levine, B. L., et al. (2017). Challenges in manufacturing CAR-T cells. Cytotherapy, 19(8), 931-938. doi: 10.1016/j.jcyt.2017.05.011

64) Kalos, M., et al. (2011). T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Science Translational Medicine, 3(95), 95ra73. doi: 10.1126/scitranslmed.3002561
65) Lamers, C. H., et al. (2013). Route of administration modulates the therapeutic efficacy of CAR-T cells. Cancer Research, 73(11), 3139-3149. doi: 10.1158/0008-5472.CAN-12-4104